查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1970687

全球結核病診斷市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Tuberculosis Diagnostics Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 117 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計結核病診斷市場將從 2025 年的 294 萬美元成長到 2034 年的 497 萬美元，2026 年至 2034 年的複合年成長率為 6.03%。

隨著醫療系統將感染疾病的早期發現和有效控制列為優先事項，結核病診斷市場正在迅速發展。傳統的診斷方法，例如痰液塗片顯微鏡檢查，正逐漸被先進的分子檢測、γ-干擾素釋放試驗和快速照護現場所補充和取代。人們對多重抗藥性結核病的日益關注，正在加速高靈敏度和高特異性診斷工具的應用。

未來的發展預計將專注於自動化、小型化和數位化連接。次世代定序技術和人工智慧增強的診斷演算法可望提高準確性、縮短檢測時間，並為臨床醫生提供實用資訊。尤其是在資源匱乏的環境中，攜帶式診斷平台的普及使得分散式檢查成為可能，並使患者能夠快速獲得醫療保健服務。診斷技術與行動醫療平台的整合正在建構能夠全面管理監測、監控和治療依從性的系統。

全球衛生舉措、政府計畫以及旨在根除結核病的公私合營進一步增強了市場前景。新型生物標記和先進成像技術的研發投入不斷增加，預計將進一步鞏固診斷生態系統。隨著創新加速和全球意識的不斷提高，結核病診斷市場有望在減輕全球疾病負擔方面發揮關鍵作用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球結核病診斷市場：按類型分類

  • 市場分析、洞察與預測
  • 潛伏感染的檢測（皮膚試驗和γ-干擾素釋放試驗）
  • 噬菌體檢測
  • 抗菌藥物抗藥性檢測（DST）
  • 核酸檢測
  • X光影像
  • 細胞激素檢測分析
  • 其他

第5章：全球結核病診斷市場：依最終用途分類

  • 市場分析、洞察與預測
  • 診斷檢查室
  • 醫院和診所
  • 其他

第6章 全球結核病診斷市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Abbott
    • Qiagen
    • Thermo Fisher Scientific Inc
    • BD
    • F. Hoffmann-La Roche AG
    • Hologic Inc
    • Cepheid
    • DiaSorin SPA
    • Hain Lifescience GmbH
    • Oxford Immunotec
簡介目錄
Product Code: VMR112110315

The Tuberculosis Diagnostics Market size is expected to reach USD 4.97 Million in 2034 from USD 2.94 Million (2025) growing at a CAGR of 6.03% during 2026-2034.

The tuberculosis diagnostics market is evolving rapidly as healthcare systems prioritize early detection and effective management of this infectious disease. Traditional diagnostic methods, such as sputum microscopy, are being supplemented and replaced by advanced molecular tests, interferon-gamma release assays, and rapid point-of-care solutions. Growing concerns over multidrug-resistant tuberculosis are accelerating adoption of highly sensitive and specific diagnostic tools.

Future developments will emphasize automation, miniaturization, and digital connectivity. Next-generation sequencing and AI-enhanced diagnostic algorithms are expected to improve accuracy, reduce turnaround times, and provide actionable insights for clinicians. Portable diagnostic platforms are gaining traction, particularly in low-resource settings, enabling decentralized testing and faster patient access to care. Integration of diagnostics with mobile health platforms is creating comprehensive systems for monitoring, surveillance, and treatment adherence.

The market outlook is reinforced by international health initiatives, government programs, and public-private partnerships aimed at eradicating tuberculosis. Rising investments in R&D for novel biomarkers and advanced imaging technologies are expected to further strengthen the diagnostic ecosystem. As innovation accelerates and global awareness increases, the tuberculosis diagnostics market is positioned to play a crucial role in reducing disease burden worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Detection of Latent Infection (Skin Test & IGRA)
  • Phage Assay
  • Detection of Drug Resistance (DST)
  • Nucleic Acid Testing
  • Radiographic Method
  • Cytokine Detection Assay
  • Others

By End-use

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Others

COMPANIES PROFILED

  • Abbott, Qiagen, Thermo Fisher Scientific Inc, BD, F HoffmannLa Roche AG, Hologic Inc, Cepheid, DiaSorin SpA, Hain Lifescience GmbH, Oxford Immunotec
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Detection of Latent Infection (Skin Test & IGRA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Phage Assay Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Detection of Drug Resistance (DST) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Nucleic Acid Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Radiographic Method Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Cytokine Detection Assay Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET: BY END-USE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast End-use
  • 5.2. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Type
    • 6.2.2 By End-use
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Type
    • 6.3.2 By End-use
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Type
    • 6.4.2 By End-use
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Type
    • 6.5.2 By End-use
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Type
    • 6.6.2 By End-use
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL TUBERCULOSIS DIAGNOSTICS INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Abbott
    • 8.2.2 Qiagen
    • 8.2.3 Thermo Fisher Scientific Inc
    • 8.2.4 BD
    • 8.2.5 F. Hoffmann-La Roche AG
    • 8.2.6 Hologic Inc
    • 8.2.7 Cepheid
    • 8.2.8 DiaSorin S.P.A
    • 8.2.9 Hain Lifescience GmbH
    • 8.2.10 Oxford Immunotec